Patients with branch retinal vein occlusion (BRVO) treated with aflibercept had a significantly longer time before macular edema recurred compared to those treated with ranibizumab, and higher subfoveal choroidal thickness at baseline was associated with faster recurrence, according to a study.
The study included 110 treatment-naïve BRVO patients with macular edema, randomized to receive either aflibercept (2 mg) or ranibizumab (0.5 mg) injections. After at least 3 monthly injections to resolve the edema, patients were followed for 9 months to monitor recurrence.
On average, macular edema recurred after 10.7 weeks in the aflibercept group versus 8.9 weeks in the ranibizumab group (P < 0.001). However, both groups required a similar number of injections to achieve initial resolution. Greater subfoveal choroidal thickness (SFCT) and inter-eye SFCT difference at baseline were also linked to earlier recurrence.
Reference
Farrell AC, Casselholm de Salles M, et al. Recurrence of Macular Edema in Branch Retinal Vein Occlusion – a Comparison of Aflibercept and Ranibizumab in a Randomized Trial. Ophthalmol Retina. 2025;S2468-6530(25)00219-2. doi: 10.1016/j.oret.2025.05.012. Epub ahead of print. PMID: 40373873.
Related Content
